Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab

Hassan, SU, Md Yusof, MY, Emery, P orcid.org/0000-0002-7429-8482 et al. (2 more authors) (2020) Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab. Frontiers in Medicine, 7. 498. ISSN 2296-858X

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: Copyright © 2020 Hassan, Md Yusof, Emery, Dass and Vital. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Keywords: B cells, belimumab, immunogenecity, rituximab, systemic lupus erythematosus
Dates:
  • Accepted: 21 July 2020
  • Published (online): 27 August 2020
  • Published: 27 August 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 14 Oct 2020 10:46
Last Modified: 25 Jun 2023 22:27
Status: Published
Publisher: Frontiers Media SA
Identification Number: https://doi.org/10.3389/fmed.2020.00498
Related URLs:

Download

Export

Statistics